Carisoprodol

Carisoprodol is a centrally acting skeletal muscle relaxant belonging to the carbamate class of drugs, marketed most widely under the brand name Soma ^[2]. It is prescribed for short-term relief of pain from acute muscle strains, sprains, and similar injuries, and is meant to be used together with rest and physical therapy rather than on its own ^[2]. Although classed as a muscle relaxant, it does not act directly on muscle tissue; its benefit is attributed mainly to sedation of the central nervous system, which is also the source of its potential for misuse ^[1][2].

The drug was introduced around 1959, developed by Frank Berger and colleagues at Wallace Laboratories as a close chemical relative of the tranquilizer meprobamate ^[2]. In the body carisoprodol is broken down, chiefly by the liver enzyme CYP2C19, into meprobamate, a sedative that is itself a controlled substance; the parent drug is comparatively short-lived, while meprobamate persists longer, and both contribute to the overall effect ^[2][4]. Genetic differences in CYP2C19 activity can therefore influence how strongly a given person responds.

Laboratory research has clarified how carisoprodol works. Its metabolite meprobamate had long been assumed to be responsible for its sedative and muscle-relaxing effects through actions at the GABA-A receptor, the main inhibitory receptor in the brain, in a manner resembling barbiturates ^[4]. Later electrophysiological and behavioral studies showed that carisoprodol itself, not only meprobamate, directly modulates and can activate GABA-A receptors in a barbiturate-like way, and that this activity likely contributes to both its therapeutic action and its abuse potential ^[1][5]. Forensic studies have found that carisoprodol can impair driving performance, with the parent drug appearing to contribute to impairment independently of meprobamate ^[3].

Because it is converted to a controlled sedative and produces its own barbiturate-like effects, carisoprodol carries a recognized risk of tolerance, dependence, and abuse, and abrupt discontinuation after heavy use can cause a withdrawal syndrome that includes insomnia, anxiety, tremor, and, in severe cases, agitation and seizures ^[2]. Reflecting these concerns, carisoprodol was placed under federal control as a Schedule IV substance in the United States in 2012, and several European countries restricted or withdrew it from the market in the years before that ^[2].

Carisoprodol is taken by mouth, sometimes in combination products that also contain aspirin or codeine, and its most common side effects are drowsiness, dizziness, and headache. Because of the sedation it causes, it is typically prescribed only for short periods and is used cautiously alongside alcohol or other central nervous system depressants ^[2].

Carisoprodol is prescription only and a Schedule IV controlled substance. Common effects are drowsiness, dizziness and headache, and it clearly impairs driving. It carries a genuine potential for dependence, tolerance, misuse and a withdrawal syndrome that can include seizures, which is why courses are kept to two or three weeks. Combining it with alcohol, opioids or benzodiazepines causes dangerous additive central nervous system and respiratory depression and raises overdose risk. People who are CYP2C19 poor metabolizers build up higher carisoprodol levels and may feel stronger effects.

Carisoprodol produces greater abuse liability and psychomotor impairment when combined with oxycodone than either drug alone, even when doses are separated by an hour and the drugs are not at peak concentration simultaneously ^[6]. This is a pharmacodynamic interaction; both drugs depress the central nervous system through different mechanisms (muscle relaxation via GABA-A agonism for carisoprodol, opioid receptor agonism for oxycodone), and their effects on coordination, alertness, and subjective drug-liking add together.

Real-world injury rates are elevated when carisoprodol is combined with oxycodone, particularly when the muscle relaxant is started after the opioid, with a 1.86-fold hazard ratio for injury compared to patients on methocarbamol plus oxycodone ^[7]. Carisoprodol itself is not a CYP substrate of clinical significance, and opioid clearance is not substantially altered; the danger is purely synergistic depression of respiration and consciousness. What remains unstudied: the interaction with non-opioid analgesics, with benzodiazepines alone (without opioids), or with selective serotonin reuptake inhibitors; the minimal safe dosing interval between carisoprodol and opioids; and long-term tolerance or sensitization to this combination.

Checking a whole stack? Run it through interactions + stacks.